Serina Therapeutics Inc

Serina Therapeutics insider trading: Chief Scientific Officer Moreadith Randall’s 6,500‑share buy‑sell cycle reveals short‑term gains, raising questions on long‑term value and company fundamentals.

Serina Therapeutics insider buy sparks optimism: CSO’s 6,500‑share purchase and soaring social buzz hint at a possible short‑term rally amid valuation risks.

Serina Therapeutics insider trade: CSO Moreadith Randall flips shares at a premium, hinting at short‑term volatility and potential rebound after upcoming news.